HGH Frag 176-191

HGH Fragment 176-191 is a modified 16-amino acid segment of the growth hormone molecule encompassing the C-terminal region (amino acids 176 through 191) with a tyrosine modification. This fragment was specifically designed to isolate the lipolytic (fat-metabolizing) properties of full-length HGH while eliminating its growth-promoting, diabetogenic, and anti-insulin effects. Research has demonstrated that HGH Frag 176-191 stimulates lipolysis through activation of hormone-sensitive lipase (HSL) and β3-adrenergic receptor pathways in adipocytes, while simultaneously inhibiting lipogenesis by reducing acetyl-CoA carboxylase activity. Unlike full-length HGH, this fragment does not compete for the GH receptor or affect IGF-1 levels, insulin sensitivity, or blood glucose homeostasis. Preclinical studies in obese animal models have shown significant reductions in body fat mass without changes in lean tissue, food intake, or glucose tolerance. Research has also explored its potential to enhance fatty acid oxidation and improve lipid profiles, making it a focused tool for studying fat-specific metabolic pathways independent of the broader GH signaling cascade.